Enfuvirtide

Information about Enfuvirtide

Enfuvirtide is an HIV fusion inhibitor, the first of this class of agents active against the human immunodeficiency virus (HIV).

Liver safety of Enfuvirtide

Enfuvirtide has not been associated with serum aminotransferase elevations during therapy or episodes of acute, clinically apparent liver injury.

Mechanism of action of Enfuvirtide

Enfuvirtide (en fue' vir tide) is relatively new antiretroviral drug that blocks the fusion of HIV to target cell, preventing viral entry and subsequent infection. Enfuvirtide is a 36 amino acid biomimetic peptide that resembles the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. Enfuvirtide has both in vitro and in vivo activity against HIV, and several randomized controlled trials have shown that it leads to significant decline in HIV RNA levels and rises in peripheral [[CD4 T cell counts]. 

FDA approval information for Enfuvirtide

Enfuvirtide was approved for use in the United States in 2003, but it has had limited use, partially because it requires parenteral administration once or twice daily. Enfuvirtide is available in single use vials that contain 90 mg/mL after reconstitution under the brand name of Fuzeon. The recommended regimen for enfuvirtide is 90 mg subcutaneously twice daily in adults and 2 mg/kg in children ages 6 to 16. Enfuvirtide is recommended only in combination with other antiretroviral agents.

Side effects of Enfuvirtide

The only common side effects specifically linked to enfuvirtide have been injection site reactions (which can be troublesome) and eosinophilia. Regimens that include enfuvirtide have the potential to cause immune reconstitution syndrome, pneumonitis and severe hypersensivity reactions.

Antiviral agents

Drugs for HIV Infection, in the Subclass Antiretroviral Agents

• Fusion Inhibitors (HIV)
  • Enfuvirtide, Maraviroc

• Integrase Inhibitors (HIV)
  • Dolutegravir, Elvitegravir, Raltegravir

• Monoclonal Antibodies
  • Ibalizumab

• Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
  • Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine

• Nucleoside Analogues (HIV)
  • Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, Zidovudine

• Protease Inhibitors (HIV)
  • Amprenavir, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir,Ritonavir, Saquinavir, Tipranavir

Drugs for Hepatitis B

• • Alpha Interferon, Adefovir, Emtricitabine, Entecavir, Lamivudine, Telbivudine, Tenofovir

Drugs for Hepatitis C

• Interferon Based Therapies
  • Alpha Interferon and Peginterferon, Ribavirin

HCV NS5A Inhibitors

• Daclatasvir, Elbasvir, Ledipasvir, Ombitasvir, Pibrentasvir, Velpatasvir

HCV NS5B (Polymerase) Inhibitors

• Dasabuvir, Sofosbuvir

HCV Protease Inhibitors

• Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir

Combination Therapies

• Epclusa, Harvoni, Mavyret, Technive, Viekira Pak, Vosevi, Zepatier

Drugs for Herpes Virus Infections (HSV, CMV, others)

• Acyclovir, Cidofovir, Famciclovir, Foscarnet, Ganciclovir, Valacyclovir, Valganciclovir

Drugs for Influenza

• Amantadine, Oseltamivir, Peramivir, Rimantadine, Zanamivir

• Dailymed label info on Enfuvirtide
• FDA Enfuvirtide

Enfuvirtide Resources
Need Help Finding a Doctor? WikiMD's DocFinder can help find general and specialist physicians.	Latest articles Most recent articles Ongoing trials.